Non-invasive fecal biomarkers in newborns whose mothers received probiotics during 6 weeks before delivery
E.V. PODSVIROVA1, M.M. GUROVA1,2,3, T.A. ROMANOVA1
1Belgorod State National Research University of the Russian Ministry of Education, Belgorod
2Saint Petersburg State Pediatric University, Saint Petersburg
3Clinical Diagnostic Center for Children, Saint Petersburg
Contact:
Podsvirova E.V. ― Assistant Lecturer of the Department of Pediatrics with a course of Surgical Diseases
Address: 85 Pobedy Str., 308015, Belgorod, Russian Federation, tel. +7-910-323-80-83, e-mail: itely@mail.ru
Objective: to study the level of fecal biomarkers (eosinophilic neurotoxin and fecal calprotectin) in newborns depending on prescription of probiotics to pregnant women during 6 weeks before delivery.
Material and methods: 2 groups were formed: main group (n=63), which received probiotic containing 107 Bifidobacteriumlongum and Streptococcusthermophilus, and comparison group (n=52), which did not receive a probiotic. After childbirth, the level of fecal biomarkers in children was estimated on the 3-4 and 27-28 day of life.
Results: It was shown that the levels of fecal biomarkers in children of the first days of life was higher than on the 27-28 day of life, regardless of the probiotic taken by mothers before delivery, but in children of the main group both indicators were significantly lower than in the comparison group.
Conclusion: In children of the main group, the levels of fecal inflammation biomarkers was significantly lower than in children of the comparison group. Further observation of children during the first year of life showed that the children of the main group had significantly less rate of functional diseases of gastrointesntinal tract (4.8% against 32.6%, р = 0.034) and manifestations of food allergy (7.9% against 30.8%, р = 0.012).
Key words: newborns, non-invasive fecal biomarkers, fecal calprotectin, eosinophilic neurotoxin, probiotics, pregnant women.
REFERENCES
- Kapel N., Campeotto F., Kalach N., Baldassare M., Butel M.J., Dupont C. Faecalcalprotectin in term and preterm neonates. JPGN, 2010, vol. 51, no. 5, pp. 542-547.
- Vasan R.S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation, 2006, no. 113, rr. 2335-2362.
- Gurova M.M., Novikova V.P. Evolutionary aspects of neonatal gastroenterology (part 1). Voprosy detskoy dietologii, 2017, vol. 15, no. 4, pp. 37-44 (in Russ.).
- Mulder I.E., Schmidt B., Stokes C.R., Lewis M., Bailey M., Aminov R.I., Prosser J.I., Gill B.P., Pluske J.R., Mayer C.D., Musk C.C., Kelly D. Environmentally-acquired bacteria influence microbial diversity and natural innate immune responses at gut surfaces. BMC Biol, 2009, vol. 7, p. 79.
- Roca M., Varela A.R., Donat E., Cano F., Hervas D., Armisen A., Vaya M.J., Sjolander A., Ribes-Koninckx C. Fecal calprotectin and eosinophil-derived neurotoxin in healthy children between 0 and 12 years. JPGN, 2017, vol. 65, no. 4, rr. 394-398.
- Dale I., Fagerhol M.K., Naesgaard I. Purification and partial characterization of highly immunogenic human leukocyte protein, the L1 antigen. Eur J Biochem, 1983, no. 134, rr.1-6.
- Kalach N., Kapel N., Waligora-Dupriet A.J., et al. Intestinal permeability and fecal eosinophil-derived neurotoxin are the best diagnosis tools for digestive non-IgE-mediated cow’s milk allergy in toddlers. ClinChem Lab Med, 2013, no. 51, rr. 351-361.
- Walker W.A. Gastrointestinal host defense: importance of gut closure in control of macromolecular transport. Ciba Found Symp, 1979, rr. 201-219.
- Berstad A., Arslan G., Folvik G. Relationship between intestinal permeability and calprotectin concentration in gut lavage fluid. Scand J Gastroenterol, 2000, no. 35, rr. 64-69.
- Rugtveit J., Fagerhol M.K. Age-dependent variations in fecal calprotectin concentrations in children. J Pediatr Gastoenterol Nutr, 2002, no. 34, rr. 323-325.
- Baldassarre M.E., Altomare M.A., Fanelli M. et al. Does calprotectin represent a regulatory factor in host defense or a drug target in inflammatory disease? Endocr, MetabImmunDisord Drug Targets, 2007, no. 7, rr.1-5.
- Josefsson S., Bunn S.K., DomelloF.M. Fecal calprotectin invery low birth weight infants. J PediatrGastroenterolNutr, 2007, no. 44, rr. 407-413.